Bottom line
SHPCX vs RYOIX: the short answer
SHPCX (Health & Biotechnology Portfolio) and RYOIX (Biotechnology Fund) are both mutual funds.
But RYOIX is far broader, holding 74 positions to 29 for SHPCX, so beyond the top names it adds exposure SHPCX doesn't have.
RYOIX is cheaper at 1.38% vs 3.6% — a difference of $222 a year per $10,000 invested.
Over five years, RYOIX returned +4.0% a year vs +3.7% for SHPCX (reporting dates differ).
Updated Nov 19, 2026
SHPCX vs RYOIX side by side
| SHPCX | RYOIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Saratoga Advantage | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 3.6% | 1.38% |
| Annual cost per $10k | $360 | $138 |
| 10-yr cost on $10k (prospectus) | $3,862 | $1,709 |
| Max front load | 0% | — |
| 12b-1 fee | — | 0% |
| 1-yr return | −1.3% | +30.7% |
| 5-yr return (annualized) | +3.7% | +4.0% |
| 10-yr return (annualized) | +4.1% | +5.9% |
| Best quarter | +15.0% | +28.3% |
| Worst quarter | −13.0% | −22.5% |
| Net assets (fund) | $10.5M | $136.8M |
| Number of holdings | 29 | 74 |
| Portfolio turnover | 22% | 75% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHPCX | RYOIX | Difference |
|---|---|---|---|
| 2024 | −0.3% | −0.7% | +0.4% |
| 2023 | −0.9% | +6.1% | −7.0% |
| 2022 | +1.4% | −13.1% | +14.5% |
| 2021 | +16.0% | +1.8% | +14.2% |
| 2020 | +3.0% | +22.1% | −19.1% |
| 2019 | +15.4% | +25.0% | −9.6% |
| 2018 | −6.0% | −9.0% | +3.0% |
| 2017 | +11.3% | +29.7% | −18.5% |
| 2016 | −2.5% | −19.5% | +17.0% |
Source: Fund prospectus bar charts
Holdings overlap
6 of SHPCX's top 25 holdings also appear in RYOIX's top 25.
| Holding | SHPCX | RYOIX |
|---|---|---|
| United Therapeutics Corp | 6.17% | 1.72% |
| Amgen Inc | 5.04% | 5.05% |
| Gilead Sciences Inc | 3.94% | 4.49% |
| Regeneron Pharmaceuticals Inc | 3.93% | 2.93% |
| Vertex Pharmaceuticals Inc | 3.36% | 4.32% |
| Incyte Corp | 2.89% | 1.62% |
Source: SEC Form N-PORT
SHPCX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between SHPCX and RYOIX?
Which is cheaper, SHPCX or RYOIX?
Should I own both SHPCX and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.